Amgen (AMGN) said Friday that a phase 3 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung cancer met its primary endpoint at a planned interim analysis.
The biopharmaceutical company said the data show that Imdelltra demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
Amgen said the randomized open-label clinical trial is evaluating the efficacy and safety of Imdelltra as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。